On August 3, 2026 Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation macrophage-directed immunotherapies for cancer, reported it will host an educational webinar on Monday, August 10, 2026 from 12:00 p.m. – 2:00 p.m. ET. The webinar will focus on the emerging role of macrophage checkpoint biology for the treatment of solid tumors as well as Pheast’s lead program, PHST001, a novel, high-affinity IgG4 anti-CD24 monoclonal antibody currently in Phase 1 clinical development for multiple solid tumor types, including ovarian cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webinar will feature participation from key opinion leaders (KOLs) in cancer immunotherapy:
Aurélien Marabelle, M.D., Ph.D., Professor of Clinical Immunology, University of Paris Saclay; Senior Medical Oncologist in the Drug Development Department (DITEР) at Gustave Roussy Cancer Center; and Head of the Laboratory for Translational Immunotherapy Research (LRTI)
Thomas Marron, M.D., Ph.D., Professor of Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai and Associate Director for Translational Research at Tisch Cancer Center
Please click here to register for the live webinar. A replay of the webinar will also be made available under the Presentations section of the Pheast Therapeutics website following the live event.
About PHST001
PHST001 is an anti-CD24 macrophage checkpoint inhibitor designed to overcome immune suppression in the tumor microenvironment. CD24 is highly expressed across many cancers, where high expression is associated with poor prognosis. Pheast has engineered PHST001 to be a potential best-in-class antibody designed to induce macrophages to phagocytose cancer cells and initiate a powerful immune response. PHST001-101 is an open-label, multicenter Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT06840886) evaluating safety, tolerability, and dose optimization, with secondary objectives assessing pharmacokinetics and preliminary anti-tumor activity. PHST001 received FDA Fast Track Designation for the treatment of ovarian cancer in June 2025.
(Press release, Pheast Therapeutics, AUG 3, 2026, View Source [SID1234669624])